Eagle Country

I Can Extract Side Effects

Contents

鹰国
Swipe to browse
Entity Info
Original Name:鹰国Gender:NeutralScope:Novel-specificStatus:ActiveSource:AIOccurrences:1034Chapters:243
0views
Context UptoCh. 668
Wiki ModelGPT-5.6 Terra
Image ModelGPT Image 2
Updated3 weeks ago
Novel Codex

Biodata

Feature Details
Name Eagle Country
Alias(es) 鹰国
Occupation/Role Major overseas pharmaceutical market, technological competitor, and geopolitical counterpart to China
First Appearance 45

Background / History

Eagle Country is portrayed as a dominant but internally conflicted overseas power, particularly in pharmaceuticals, biotechnology, medical regulation, and aerospace. Its large drug market, FDA approvals, research institutions, media outlets, wealthy elites, and government agencies repeatedly shape Sanqing Group's overseas expansion. The country is also depicted as having high medical costs, powerful pharmaceutical interests, and recurring public pressure for access to Sanqing's medicines.

Story Role / Major Arcs

Period Events Chapters
Early pharmaceutical conflict Pharmaceutical interests pressure an FDA official to delay Sanqing's anticancer-drug approval. The FDA later attributes the obstruction to arrested official Josen and promises expedited approval. 38 45
Medical-tourism setting Chinese patient Li Senqiang brings his father to Eagle Country for treatment, citing its cancer centers, newer drugs, and proton radiation therapy. 46
AD Special Effect Drug dispute Fox News accuses Sanqing of technology theft; Sanqing responds by suspending applications for Eagle Country clinical trials and market entry. Patients, their families, and wealthy elites subsequently pressure the FDA to bring in Sanqing's Alzheimer's drug. 89 90 96
Domestic research countermeasure Eagle Country allocates $1 billion annually for five years to domestic research into human brain neural stem cells, intending to compete with and block Sanqing's work in the field. 108
Recruitment and espionage An Eagle Country agency exploits Sanqing's recruitment of overseas talent by placing an operative within the company. Williams is later exposed as an outsourced operative who supplied Sanqing's research-progress information. 109 162 397
Weight-loss-drug approval Public petitions by obese residents push the FDA to invite Sanqing to apply for approval of its weight-loss drug; the application is quickly approved. 129
Non-addictive painkiller ban The FDA issues a sales ban against Sanqing's non-addictive painkiller before Sanqing has even applied for approval. The ban occurs amid Eagle Country's widespread opioid-painkiller abuse. 136
Rare-disease and insulin activism High medicine prices fuel pressure against pharmaceutical monopolies. Eagle Country hospitals seek Sanqing as a supplier of generic rare-disease drugs, while local bio-hackers collaborate with Chinese counterparts on the Open Insulin Project. 185 190 195 196
Patent war Sanqing and the Broad Institute enter a patent and anti-monopoly dispute in Eagle Country. Sanqing later suspends its drug sales there over FDA discrimination, prompting patient protests before the Broad Institute withdraws its lawsuit. 270
FDA negotiations The FDA proactively invites Sanqing to conduct thalassemia gene-therapy trials in Eagle Country. Wei Kang demands the lifting of a painkiller ban and fast-track approvals; the FDA agrees to lift the ban while retaining the option to reinstate it. 255
Space-technology controversy NASA faces pressure after China refuses commercial-spaceflight cooperation with Mabus's Mars Group. NASA then promotes a portable astronaut monitor, but footage reveals that it uses Sanqing technology and has questionable accuracy. 348 349
High-priced Sanqing drug listing Sanqing's Severing Love Spirit receives FDA approval. It is sold for $2,000 per bottle in Eagle Country, far above its price in China and Europa, provoking outrage despite continuing demand. 374
Talent loss Williams publicly joins Chinese nationality after working at Sanqing. Eagle Country media, scholars, and netizens condemn his decision, while his former supervisor attempts to persuade him to return. 397 398
Environmental-health pressure Frequent chemical leaks and resulting public protests accelerate the Eagle Country launch of Xifuning. Sanqing personnel warn that released toxins may cause long-term environmental and health damage. 541
Sports and therapeutic-use exemptions Eagle Country athletes are described as extensively using therapeutic-use exemptions for prohibited drugs. Zhao Kun anticipates that Eagle Country athletes could seek exemptions to use Sanqing's high oxygen-carrying nanoparticles. 619 623

Pharmaceutical Market and Healthcare

  • Eagle Country is described as accounting for 40% of the global pharmaceutical market, making it a strategically important but difficult market for Sanqing. 136
  • FDA approval is treated as especially influential internationally, as other countries often reference FDA clinical data and standards when reviewing drugs. 98
  • Its healthcare system includes commercial insurance, government health insurance for the elderly, and medical assistance for low-income individuals; roughly one-third of the population is stated to have government-provided coverage, while 9% have no insurance. 99
  • The country is repeatedly associated with high drug prices, including expensive cancer medicines, rare-disease drugs, insulin, and Sanqing's overseas products. 45 170 185 374 511
  • Insulin prices are stated to have risen by 600% over 20 years, with patients averaging $375 monthly and sometimes paying up to $1,000. 511
  • Public activism—including petitions, protests, and patient campaigns—repeatedly influences FDA decisions and market access for Sanqing drugs. 96 129 270

Key Institutions

Food and Drug Administration (FDA)

  • Regulates Sanqing's access to Eagle Country's pharmaceutical and medical-device markets. 98
  • Its officials are shown delaying approvals under pharmaceutical-industry pressure, banning Sanqing's painkiller, negotiating restrictive conditions, and later responding to organized patient pressure. 38 129 136 255
  • FDA official Davis approves Sanqing's weight-loss drug after petitions intensify, but initially notes that Juwai smartwatch ECG functions lack medical-device approval. 129 316

Eagle Country Agencies

  • An unnamed agency plants Williams at Sanqing through recruited overseas talent, hoping to obtain internal intelligence and eventually Sanqing's AI-related technology. 109 162 255
  • The agency's operatives Saul and Chris view Sanqing's overseas recruitment as an opportunity for infiltration. 109

NASA

  • NASA is portrayed as struggling with an aging International Space Station and losing influence as other countries pursue cooperation with China's Tiangong Space Station. 347 348 352
  • Director Nelson promotes a purportedly domestic portable monitor for astronauts, only for evidence to surface that the device relies on Sanqing technology. 349

Relationships

  • Sanqing Group / Wei Kang — Eagle Country is one of Sanqing's most important overseas markets, but also a repeated source of regulatory, media, patent, and intelligence conflicts. 89 136 255 270
  • FDA — The country's drug regulator; alternates between obstructing Sanqing products and approving them under public or political pressure. 45 96 129 255
  • Williams Goodman — Initially an Eagle Country-linked operative inside Sanqing; later renounces his former nationality and becomes a Chinese citizen. 162 397 398
  • Mabus and Mars Group — Mabus is an Eagle Country technology entrepreneur who admires Wei Kang and seeks spaceflight cooperation involving Sanqing technology. 151 348
  • Broad Institute — Participates in Eagle Country litigation against Sanqing during the gene-editing patent war before withdrawing its lawsuit. 270
  • Eagle Country patients and activists — Frequently pressure authorities to approve, import, or lower the price of Sanqing medicines. 96 129 185 270 374